| Followers | 2422 |
| Posts | 92347 |
| Boards Moderated | 1 |
| Alias Born | 09/12/2003 |
Tuesday, June 13, 2023 12:10:41 PM
Good times ahead! SPIN-OFF
In a spin-off, the shares of the subsidiary company of the spun-off company are distributed as special dividends by the parent company on a pro-rata basis. The parent company usually does not receive any cash consideration for undertaking the spin-off.
The company announced the intention to spin off its Livestock Impact Division as a wholly-owned subsidiary.
Announced the Signing of a License for Eye Health due to Myopia and Presbyopia; a Patent Valued at US$ 570,000,000
Signs Non-Exclusive License With LY Research to Market Patented Product for Glucose Management a patent valued at Valued at US$210,000,000
Launching of Weight Management System Including an AI Supported Body Composition Measuring App and New Health Products
Establishes a Wholesale Division to Expand Marketing Presence in a USD 151.9 Billion Global Dietary Supplement Market
https://finance.yahoo.com/quote/BDPT
https://www.shopbioadaptives.com/
The Board of Directors - Internationally Acclaimed Health Scientist, Author and Patent Holder, Dr. Yaguang Liu
Patents by Inventor Yaguang Liu
https://patents.justia.com/inventor/yaguang-liu
Who is Dr Yan Liu?
Yaguang Liu is the founder of L.Y. Research Corporation located in New Jersey. He has received 32U.S. patents of pure and safe natural botanicals, used for treatment of cancer and cardiovascular and other diseases.
L Y RESEARCH CORP is a New Jersey Domestic Profit Corporation filed on February 22, 2005. The company's filing status is listed as Active and its File Number is 0400083584.
Appointment to the Board of Directors - Visionary Futurist , Wellness Pioneer and Marketer, David Allen, PhD to its Board of Directors.
He has more than 30 years of experience developing and marketing wellness products in North America, Europe, and Asia.
David Allen, PhD is a visionary futurist and wellness pioneer. He is CEO of World Wellness and co-founder and President of the American Botanical Drug Association.
Products now sell on Amazon
More new products to launch soon, according to the company!
Our product lines include PluriCell®, PluriPain®, and PrimiLung™ for humans along with Equine All-in-One™ and a related Booster for horses.
The Company also markets the Lung Cleanser™ medical device, which is sold with our PrimiLung® product as part of a Lung Armor™ package. Additionally, the company acquired patent rights to a method to embed oxygen in water and is developing commercial products based on this technology that will augment and complement our current product lines.
In February 2022, the Company acquired US Patent rights to a process that increases dissolved oxygen in water. The process produces MorO2, ingestion of which is believed to increase diffusion of oxygen into muscle tissues. The Company is developing a business plan to manufacture and market products based on the MorO2 technology.
SUBSEQUENT EVENTS
In April 2023, Dr. Yaguang Liu of LY Research and Dr. David Allen joined the Company’s Board of Directors. Dr Liu is a renowned researcher and scientist in botanical drugs development with 32 patents under his name. Dr. David Allen, CEO of World Wellness, is a well-known developer and marketer of nutraceutical products, as well as being the co-founder and President of the American Botanical Drug Association. The Company intends to explore the botanical drug markets in both animal and human sectors. The Company also extended its participation in the Amazon marketplace where its human products, including the Lung Cleanser™, are now available. To further its animal marketing efforts, its LiveStock Impact Division signed an exclusive distribution agreement with the Flying C Bar Ranch (FCBR) Therapy Division to market its equine and canine products. FCBR is well established and connected with a substantial clientele of both walk-in and digital clients in the equine industry.
The Company has started to explore the Botanical Drugs sphere. We intend to collaborate with Dr. Yaguang Liu, LY Research, who has had over 40 years of research and development in the Botanical Drugs area. Also, we plan to work with Dr. David Allen, the co- founder and President of the Botanical Drugs Association in this effort
Effective November 15, 2021, the Company entered into a marketing agreement for an FDA-cleared medical device, the Lung Flute™, which the Company called Lung Cleanser. The Company is also exploring agreements with other medical device manufacturers; the owners of intellectual property relating to medical devices and processes; and marketing companies associated with these manufacturers and owners
Effective February 2, 2022, the Company acquired the option to purchase U.S. Patent No. 9,783,432B (the “Patent”), covering technology used in enhancing the capability of water to hold significantly larger amounts of oxygen. Since June 6, 2022, we entered into a services agreement with Wildpack Beverages in Las Vegas, Nevada to co-pack a pilot run (1333 cases) of this Product.
Market and Marketing
We market our science-based, quality nutraceuticals to a broad base of the population in the U.S., and are exploring marketing prospects in Asia, Australasia, the Middle East, and Europe. The Company’s current target markets also include equine and canine companion animals and equine competitors in the U.S., Australasia and the Middle East.
Investors
https://www.shopbioadaptives.com/pages/investors
Reporting Status Audited Financials
U.S. Reporting: SEC Reporting
HISTORY NO R/S
Market Cap Market Cap
211,496 - 06/12/2023
Authorized Shares 1,250,000,000 - 05/31/2023
Outstanding Shares - 422,991,798 - 05/31/2023
Restricted 15,491,267- 05/31/2023
Unrestricted 407,500,531 - 05/31/2023
Held at DTC 404,629,298 - 05/31/2023
Recent BDPT News
- BioAdaptives introduces MyndSystem™, an integrated Neuro-Performance & Repair system for day and night • GlobeNewswire Inc. • 04/28/2026 02:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/14/2026 08:05:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 02:45:46 AM
- BioAdaptives® Announces Commercial Launch of MyndMed™ Following Successful Pilot Testing • GlobeNewswire Inc. • 10/07/2025 03:48:03 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 07:16:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2025 08:05:36 PM

